Released May 7, 2026, before the open
10-Q filed May 7, 2026, 37 days after period end · 0001628280-26-031671
Q1 2026 · 10-Q
Revenue$3.27M$3.27M −45.1% vs Q1 2025−64.7% vs Q4 2025
Net Income-$19.88M-$19.88M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.29-$0.29 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$21,573,000N/M
Operating Cash Flow-$25,266,000N/M
Free Cash Flowderived-$25,266,000N/M
Margins · derived
Operating margin-660.3%−275.4 pt vs Q1 2025
Net margin-608.4%−291.9 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $3.27M | $5.95M | $5.05M | $5.31M |
| Net Income | -$19.88M | -$18.83M | -$25.02M | -$30.49M |
| EPS Diluted | -$0.29 | -$0.30 | -$0.59 | -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR